EntryPoint Capital LLC Sells 15,296 Shares of Guardant Health, Inc. (NASDAQ:GH)

EntryPoint Capital LLC lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 48.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,337 shares of the company’s stock after selling 15,296 shares during the quarter. EntryPoint Capital LLC’s holdings in Guardant Health were worth $499,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new stake in Guardant Health in the third quarter worth $754,000. Cerity Partners LLC grew its stake in shares of Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after acquiring an additional 68,883 shares during the period. Advantage Alpha Capital Partners LP purchased a new stake in Guardant Health in the 3rd quarter worth about $343,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Guardant Health by 6.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock valued at $665,000 after acquiring an additional 1,844 shares during the period. Finally, Verition Fund Management LLC lifted its holdings in Guardant Health by 220.6% during the third quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock valued at $863,000 after purchasing an additional 25,900 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Guardant Health stock opened at $46.46 on Wednesday. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The stock has a market cap of $5.73 billion, a P/E ratio of -13.05 and a beta of 1.50. The firm’s fifty day moving average price is $44.20 and its 200-day moving average price is $33.95.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analyst Weigh In

GH has been the topic of several research reports. Guggenheim reissued a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Scotiabank boosted their target price on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. Barclays started coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target for the company. The Goldman Sachs Group boosted their price objective on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Stifel Nicolaus raised their target price on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Guardant Health has an average rating of “Buy” and a consensus target price of $48.40.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.